Group 1 - The company has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for its innovative drug BEBT-701, which targets both AGT and PCSK9 for the treatment of mild to moderate hypertension combined with elevated LDL cholesterol [1][2] - BEBT-701 is developed using the proprietary GalNAc dual oligonucleotide conjugate (GDOC) technology platform, aiming to provide a comprehensive management solution for high cardiovascular risk populations through a single administration that simultaneously regulates blood pressure and lipid levels [2][3] - According to the World Health Organization, approximately 1.4 billion people globally suffer from hypertension, with around 245 million adults in China affected, highlighting the significant market potential for BEBT-701 in addressing cardiovascular diseases [3]
广州必贝特医药股份有限公司 自愿披露关于BEBT-701临床试验申请 获得国家药品监督管理局批准的公告